Full Press Release Details
Laboratory Testing and Sales Distribution Update
Kelowna, BC / July 28, 2015 / Lexaria, Corp. (OTCQB:LXRP)
(CSE:LXX) (the Company ) provides the following information to update both the
status of the ongoing laboratory testing; and, of progress with sales and
On May 20, Lexaria announced that it was to commence third
party in vitro tests using a human intestinal tissue model to evaluate
the cannabidiol (CBD) permeability of its patent-pending technology that infuses
cannabinoid compounds within lipids. The tests are expected to provide third
party evidence of the superior absorption characteristics available through
Lexaria s patent-pending technology. On May 20 the Company stated that results
are expected within 3-4 months.
Lexaria is pleased to report that the studies are progressing
favorably, with initial phases wrapped up and the final testing phase currently
in progress. This final testing phase should be complete around mid-August, with
results available in late August.
Lexaria initiated these third party in vitro tests to
provide scientific evidence of the performance of its patent pending absorption
technology. The Company expects a positive outcome to these tests which may be
unique in the entire industry.
SALES AND DISTRIBUTION
Lexaria is pleased to report that in recent weeks we have
experienced an increase in sales and in retail distribution enquiries. June of
2015 marked the Company s first on-the-ground sales and market intelligence
efforts with professional sales consultants making our first face-to-face sales
and market intelligence visits. Store owners and managers were asked to provide
feedback on the ViPovaTM tea products, and this market data was used
to optimize subsequent offerings and procedures.
Sales consultants are currently engaged in face-to-face sales
calls in two cities, including the San Francisco Bay area, one of the country s
most important urban markets. The current sales efforts have already been
successful. Additional medical marijuana dispensaries are carrying the
ViPovaTM product line, and we are adding new sales locations, often
The Company s strategy earlier this year had been to Get it
Right before we Get Big . We have since optimized manufacturing techniques in
order to lower costs to the consumer while maintaining profitable manufacturing
operations for shareholders. We ve expanded trade advertising in some of the
most widely read magazines in the medical marijuana industry, and attended
several industry conferences to introduce ViPovaTM tea.
Lexaria is also poised to introduce new product flavors and
entirely new products in August and September. The new products, together with
growing awareness of Lexaria and its ViPovaTM line of products, are
expected to assist in meeting demand from our growing network of distributors and provide customers an array of flavors in
convenient to use, cost effective servings. New products and an ever increasing
network of physical sales locations should lead to a marked increase in sales in
the weeks and months to come.
Lexaria s consulting sales force is expected to continue
targeting individual cities for most of the rest of 2015. In addition,
discussions have begun with other professional sales consultants to possibly
begin a more national sales effort also in 2015. ViPovaTM hemp-based
CBD teas are federally legal in the USA giving Lexaria a strong advantage over
companies that deliver THC in their products and are thus often prevented from
engaging in interstate commerce. As 2015 unfolds, the Company plans to exploit
this advantage by engaging in increasingly active nearly-national sales
campaigns. These sales efforts, combined with what will be the industry s newest
and most technologically advanced product line focused on impressive
bio-absorption rates, are hoped to begin to deliver more significant sales
revenues through the rest of 2015.
Lexaria s technology is designed to allow for higher
bioavailability rates for THC and for CBD than is possible without lipophilic
enhancement technology. This can allow for lower overall dosing requirements
and/or higher effectiveness in active molecule delivery. Lexaria s innovative
lipid formulation process is designed to allow the delivery of molecules such as
are contained within hemp oil without the harmful side effects of ingestion via
smoking, and should be embraced for the benefits to public health.
Lexaria is a food sciences company focused on the delivery of
hemp oil compounds procured from legal, agricultural hemp, through gourmet foods
based upon its proprietary infusion technologies. www.lexariaenergy.com
ViPovaTM uses only legal hemp oil extracts, grown
from agricultural hemp in locations where it is legal to do so, in
ViPovaTM-branded tea. ViPovaTM uses its patent-pending
process to infuse concentrated amounts of hemp oil within lipids in its tea,
providing more bioactivity and comfort to the body during the absorption
process. Only ViPovaTM has this ground-breaking technology for hemp
oil/lipid infusion. www.vipova.com
FOR FURTHER INFORMATION PLEASE CONTACT:
FORWARD-LOOKING STATEMENTS
This release includes forward-looking statements. Statements
which are not historical facts are forward-looking statements. The Company makes
forward-looking public statements concerning its expected future financial
position, results of operations, cash flows, financing plans, business strategy,
products and services, competitive positions, growth opportunities, plans and
objectives of management for future operations, including statements that
include words such as "anticipate," "if," "believe," "plan," "estimate,"
"expect," "intend," "may," "could," "should," "will," and other similar
expressions are forward-looking statements. Such forward-looking statements are
estimates reflecting the Company's best judgment based upon current information
and involve a number of risks and uncertainties, and there can be no assurance
that other factors will not affect the accuracy of such forward-looking
statements. Access to capital, or lack thereof, is a major risk and there is no
assurance that the Company will be able to raise required working capital.
Factors which could cause actual results to differ materially from those
estimated by the Company include, but are not limited to, government regulation,
managing and maintaining growth, the effect of adverse publicity, litigation,
competition and other factors which may be identified from time to time in the
Company's public announcements and filings. There is no assurance that the
medical marijuana, hemp oil sector, or alternative health businesses will
provide any benefit to Lexaria, or that the Company will experience any growth
through participation in these sectors. There is no assurance that existing
capital is sufficient for the Company's needs or that it will need to attempt to
raise additional capital. There is no assurance that any planned corporate